Program
Atropine
Also written as “Atropine Sulfate”, “Low dose atropine sulfate eye drops” and “atropine sulfate”.
Its studies are mostly in Myopia · Myopia, Degenerative · Insulin Resistance · Rhinitis, Allergic, Seasonal, led by 14 companies.
Drug pageAtropine: every studyMany companies study it; this page follows only the 17 they lead. All 125 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hai Yen Eye Careits history only | 20 open or running | phase 1since Sep 27, 2018 | Sep 27, 2018 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 20 open or running | phase 1since Mar 23, 2022 | Mar 23, 2022 | none ahead |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceuticalits history only | 22 open or running | phase 3since Jan 5, 2024 | Jan 5, 2024 | none ahead |
| Cloudbreak Therapeuticsits history only | 10 open or running | phase 2since May 5, 2021 | May 5, 2021 | none ahead |
| Eyenoviaits history only | 10 open or running | phase 3since May 7, 2019 | May 7, 2019 | none ahead |
| IDB VisionCare SDN BHDits history only | 11 open or running | phase 3since Sep 16, 2025 | Sep 16, 2025 | Sep 2027phase 3 · NCT07329777 |
| Kubota Pharmaceuticalits history only | 11 open or running | no phasesince Aug 26, 2023 | Aug 26, 2023 | none ahead |
| Magna Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 26, 2014 | Feb 26, 2014 | none ahead |
| MicroDose Defense Productsits history only | 10 open or running | phase 1since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| Ocumension Therapeutics (Suzhou)its history only | 10 open or running | phase 3since Nov 18, 2024 | Nov 18, 2024 | none ahead |
| Ocus Innovation Irelandits history only | 11 open or running | phase 3since May 23, 2025 | May 23, 2025 | Dec 31, 2027phase 3 · NCT07028827 |
| SciMar | 10 open or running | no phasesince Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Sydnexisits history only | 10 open or running | phase 3since Apr 12, 2019 | Apr 12, 2019 | none ahead |
| Zhaoke (Hong Kong) Ophthalmology Pharmaceuticalits history only | 11 open or running | phase 1since Apr 23, 2023 | Apr 23, 2023 | none ahead |
- Named in jiangsu hengrui medicine’s own pipeline as
Atropine eye drops
, phase 4, as of Jul 31, 2026 (source).
Also a collaborator on its studies: Euromed Pharma Services SRL, Novotech (Australia) Pty, Source Nutraceutical and Brien Holden Vision.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of SciMar only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2020First study: no phase study in Insulin ResistanceFirst studyNCT04625088 · 24 enrolled · Canada
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
Studies
The one study SciMar leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04625088Insulin Resistance · Canada | – | Completed | Aug 6, 2021 | 24 |
How it is read
Names in the registry
- “Atropine Sulfate”, 3 entries
- “Low dose atropine sulfate eye drops”, 3 entries
- “atropine sulfate”, 2 entries
- “SYD-101 0.01%”, 1 entry
- “SYD-101 0.03%”, 1 entry
Conditions, from the studies’ own filings
- Myopia, 12 studies
- Myopia, Degenerative, 1 study
- Insulin Resistance, 1 study
- Rhinitis, Allergic, Seasonal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.